MRC: research grant: applicant-led
Medical Research Council
What it funds
Word limit: 550 In plain English, provide a summary we can use to identify the most suitable experts to assess your application. We usually make this summary publicly available on external-facing websites, therefore do not include any confidential or sensitive information. Make it suitable for a variety of readers, for example: opinion-formers policymakers the public the wider research community Guidance for writing a summary Clearly describe your proposed work in terms of: context the challenge
Who can apply
To be eligible to apply for this funding opportunity you must show that you will direct the project and be actively engaged in the work. For applicants who do not have a contract of employment for the duration of the proposed project, by submitting an application, the research organisation is confirming if it is successful: contracts will be extended beyond the end date of the project all necessary support for the project and the applicants will be provided, including mentorship and career development for early career researchers
Last checked against the official source within the last 7 days. Scheme parameters are set by the funder and can change — verify before applying, or let us do it for you.
Related schemes
Innovate UK Grant Competitions
Innovate UK
Rolling portfolio of themed R&D grant competitions for UK businesses, typically funding 25-70% of project costs across feasibility, industrial research and experimental development.
Knowledge Transfer Partnerships (KTP)
Innovate UK / UKRI
Funds a high-calibre graduate (Associate) plus academic team embedded in your business for 12-36 months to deliver a strategic innovation project. SMEs typically pay ~33% of project costs.
R&D Tax Relief (Merged Scheme & ERIS)
HMRC
Corporation tax relief on qualifying R&D expenditure. Merged scheme gives a 20% above-the-line credit (~15-16% net); loss-making R&D-intensive SMEs can claim enhanced support (ERIS) worth up to ~27p per £1 of qualifying spend.